首页 > 最新文献

Journal of the Chinese Medical Association最新文献

英文 中文
ChatGPT surges ahead: GPT-4 has arrived in the arena of medical research. ChatGPT突飞猛进:GPT-4已经进入医学研究领域。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-01 DOI: 10.1097/JCMA.0000000000000955
Ying-Mei Wang, Tzeng-Ji Chen
{"title":"ChatGPT surges ahead: GPT-4 has arrived in the arena of medical research.","authors":"Ying-Mei Wang, Tzeng-Ji Chen","doi":"10.1097/JCMA.0000000000000955","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000955","url":null,"abstract":"","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 9","pages":"784-785"},"PeriodicalIF":3.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10196650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immediate CT change after thrombectomy predicting symptomatic hemorrhagic transformation. 取栓后即刻CT变化预测症状性出血转化。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-09-01 DOI: 10.1097/JCMA.0000000000000958
Shang-Jung Yang, Yueh-Hsun Lu, Yi-Chen Huang, Lung Chan, Wei-Yi Ting

Background: The prognostic value of contrast accumulation from noncontrast brain computed tomography (CT) conducted immediately after intra mechanical thrombectomy (MT) in patients with acute ischemic stroke to predict symptomatic hemorrhage was studied.

Methods: Patients with acute ischemic stroke treated using MT between February 2015 and April 2019 were included. Contrast accumulation was defined as a high attenuation area observed on noncontrast brain CT conducted immediately after thrombectomy treatment, and the patients were categorized into (1) symptomatic hemorrhage, (2) asymptomatic hemorrhage, and (3) no hemorrhage according to the presence of hemorrhagic transformation and their clinical conditions. The pattern and extent of contrast accumulation were compared between patients with and without symptomatic hemorrhage. The maximal Hounsfield unit (HU) of cortical involvement in contrast accumulation was evaluated by calculating the sensitivity, specificity, odds ratio, and area under the receiver operating characteristic (ROC) curve.

Results: In total, 101 patients with anterior circulation acute ischemic stroke were treated by endovascular intervention. Nine patients developed symptomatic hemorrhage and 17 developed asymptomatic hemorrhage. Contrast accumulation was associated with all types of hemorrhagic transformation ( p < 0.01), and cortical involvement pattern was more frequently associated with symptomatic hemorrhage ( p < 0.01). The area under the ROC curve was 0.887. The sensitivity and specificity for HU > 100 in cortical involvement predicting symptomatic hemorrhage after endovascular treatment were 77.8% and 95.7%, respectively, with an odds ratio of 77.0 (95% CI, 11.94-496.50; p < 0.01).

Conclusion: Cortical involvement of contrast accumulation with a maximal HU > 100 predicts symptomatic hemorrhage after endovascular reperfusion treatment.

背景:研究急性缺血性脑卒中患者机械内取栓(MT)后立即行非造影剂脑计算机断层扫描(CT)造影剂积累对预测症状性出血的预后价值。方法:纳入2015年2月至2019年4月间接受MT治疗的急性缺血性脑卒中患者。对比剂积聚定义为取栓治疗后立即行非对比剂脑CT观察到的高衰减区域,根据有无出血转化及临床情况将患者分为(1)有症状出血、(2)无症状出血、(3)无出血。对比有和无症状性出血患者造影剂积聚的模式和程度。通过计算敏感性、特异性、优势比和受试者工作特征(ROC)曲线下面积来评估对比积累时皮层受累的最大Hounsfield单位(HU)。结果:101例前循环急性缺血性脑卒中患者均行血管内介入治疗。有症状性出血9例,无症状性出血17例。造影剂积累与所有类型的出血转化相关(p < 0.01),而皮层受累模式与症状性出血相关更频繁(p < 0.01)。ROC曲线下面积为0.887。HU > 100在皮质受损伤预测血管内治疗后症状性出血的敏感性和特异性分别为77.8%和95.7%,优势比为77.0 (95% CI, 11.94-496.50;P < 0.01)。结论:造影剂堆积累及皮质且最大HU > 100预示血管内再灌注治疗后出现症状性出血。
{"title":"Immediate CT change after thrombectomy predicting symptomatic hemorrhagic transformation.","authors":"Shang-Jung Yang,&nbsp;Yueh-Hsun Lu,&nbsp;Yi-Chen Huang,&nbsp;Lung Chan,&nbsp;Wei-Yi Ting","doi":"10.1097/JCMA.0000000000000958","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000958","url":null,"abstract":"<p><strong>Background: </strong>The prognostic value of contrast accumulation from noncontrast brain computed tomography (CT) conducted immediately after intra mechanical thrombectomy (MT) in patients with acute ischemic stroke to predict symptomatic hemorrhage was studied.</p><p><strong>Methods: </strong>Patients with acute ischemic stroke treated using MT between February 2015 and April 2019 were included. Contrast accumulation was defined as a high attenuation area observed on noncontrast brain CT conducted immediately after thrombectomy treatment, and the patients were categorized into (1) symptomatic hemorrhage, (2) asymptomatic hemorrhage, and (3) no hemorrhage according to the presence of hemorrhagic transformation and their clinical conditions. The pattern and extent of contrast accumulation were compared between patients with and without symptomatic hemorrhage. The maximal Hounsfield unit (HU) of cortical involvement in contrast accumulation was evaluated by calculating the sensitivity, specificity, odds ratio, and area under the receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>In total, 101 patients with anterior circulation acute ischemic stroke were treated by endovascular intervention. Nine patients developed symptomatic hemorrhage and 17 developed asymptomatic hemorrhage. Contrast accumulation was associated with all types of hemorrhagic transformation ( p < 0.01), and cortical involvement pattern was more frequently associated with symptomatic hemorrhage ( p < 0.01). The area under the ROC curve was 0.887. The sensitivity and specificity for HU > 100 in cortical involvement predicting symptomatic hemorrhage after endovascular treatment were 77.8% and 95.7%, respectively, with an odds ratio of 77.0 (95% CI, 11.94-496.50; p < 0.01).</p><p><strong>Conclusion: </strong>Cortical involvement of contrast accumulation with a maximal HU > 100 predicts symptomatic hemorrhage after endovascular reperfusion treatment.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 9","pages":"854-858"},"PeriodicalIF":3.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pelvic organ prolapse: Minimally invasive approach. 盆腔器官脱垂:微创入路。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1097/JCMA.0000000000000948
Yiu-Tai Li, Chia-Pei Chang, Peng-Hui Wang
{"title":"Pelvic organ prolapse: Minimally invasive approach.","authors":"Yiu-Tai Li,&nbsp;Chia-Pei Chang,&nbsp;Peng-Hui Wang","doi":"10.1097/JCMA.0000000000000948","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000948","url":null,"abstract":"","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 8","pages":"715-716"},"PeriodicalIF":3.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10342211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical strategy for colorectal cancer with synchronous liver and extrahepatic metastases: A scoring system and decision tree model. 结直肠癌伴同步肝外转移的手术策略:评分系统和决策树模型。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1097/JCMA.0000000000000947
Chan-Wei Tseng, Hao-Wei Teng, Chun-Chi Lin, Hao-Jan Lei, Jung-Jyh Hung, Wen-Yih Liang, Cheng-Yuan Hsia, Shu-Cheng Chou, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yuan-Tzu Lan, Huann-Sheng Wang, Shung-Haur Yang, Wei-Shone Chen, Jen-Kou Lin, Jeng-Kai Jiang, Shih-Ching Chang, Gar-Yang Chau

Background: The role of hepatectomy in a specific group of patients with synchronous colorectal cancer with liver metastases (SCRLM) and synchronous extrahepatic disease (SEHD) is still unclear. The aim of this study was to evaluate the efficacy of liver surgery and define the selection criteria for surgical candidates in patients with SCRLM + SEHD.

Methods: Between July 2007 and October 2018, 475 patients with colorectal cancer with liver metastases (CRLM) who underwent liver resection were retrospectively reviewed. Sixty-five patients with SCRLM + SEHD were identified and included in the study. Clinical pathological data of these patients were analyzed to evaluate the influence on survival. Important prognostic factors were identified by univariate and multivariate analyses. The risk score system and decision tree analysis were generated according to the important prognostic factors for better patient selection.

Results: The 5-year survival rate of patients with SCRLM + SEHD was 21.9%. The most important prognostic factors were SCRLM number of more than five, site of SEHD other than the lung only, inability to achieve SCRLM + SEHD R0 resection, and BRAF mutation of cancer cells. The proposed risk score system and decision tree model easily discriminated between patients with different survival rates and identified the profile of suitable surgical patients.

Conclusion: Liver surgery should not be a contraindication for patients with SCRLM + SEHD. Patients with complete SCRLM + SEHD R0 resection, SCRLM number less than or equal to five, SEHD confined to the lung only, and wild-type BRAF could have favorable survival outcomes. The proposed scoring system and decision tree model may be beneficial to patient selection in clinical use.

背景:肝切除术在同步性结直肠癌伴肝转移(SCRLM)和同步性肝外疾病(SEHD)患者中的作用尚不清楚。本研究的目的是评估肝脏手术的疗效,并确定SCRLM + SEHD患者手术候选人的选择标准。方法:回顾性分析2007年7月至2018年10月期间475例行肝切除术的结直肠癌肝转移(CRLM)患者。65例SCRLM + SEHD患者被确定并纳入研究。分析患者的临床病理资料,评价其对生存的影响。通过单因素和多因素分析确定重要的预后因素。根据重要的预后因素生成风险评分系统和决策树分析,以便更好地选择患者。结果:SCRLM + SEHD患者5年生存率为21.9%。最重要的影响预后的因素是大于5个的SCRLM数量,除肺外的SEHD部位,无法实现SCRLM + SEHD R0切除,以及癌细胞BRAF突变。所提出的风险评分系统和决策树模型可以很容易地区分不同生存率的患者,并确定合适的手术患者的概况。结论:肝脏手术不应成为SCRLM + SEHD患者的禁忌症。完全切除SCRLM + SEHD R0、SCRLM数量小于或等于5、SEHD仅局限于肺部和野生型BRAF的患者可能具有良好的生存结果。所提出的评分系统和决策树模型在临床应用中可能有利于患者的选择。
{"title":"Surgical strategy for colorectal cancer with synchronous liver and extrahepatic metastases: A scoring system and decision tree model.","authors":"Chan-Wei Tseng,&nbsp;Hao-Wei Teng,&nbsp;Chun-Chi Lin,&nbsp;Hao-Jan Lei,&nbsp;Jung-Jyh Hung,&nbsp;Wen-Yih Liang,&nbsp;Cheng-Yuan Hsia,&nbsp;Shu-Cheng Chou,&nbsp;Hung-Hsin Lin,&nbsp;Sheng-Chieh Huang,&nbsp;Hou-Hsuan Cheng,&nbsp;Yuan-Tzu Lan,&nbsp;Huann-Sheng Wang,&nbsp;Shung-Haur Yang,&nbsp;Wei-Shone Chen,&nbsp;Jen-Kou Lin,&nbsp;Jeng-Kai Jiang,&nbsp;Shih-Ching Chang,&nbsp;Gar-Yang Chau","doi":"10.1097/JCMA.0000000000000947","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000947","url":null,"abstract":"<p><strong>Background: </strong>The role of hepatectomy in a specific group of patients with synchronous colorectal cancer with liver metastases (SCRLM) and synchronous extrahepatic disease (SEHD) is still unclear. The aim of this study was to evaluate the efficacy of liver surgery and define the selection criteria for surgical candidates in patients with SCRLM + SEHD.</p><p><strong>Methods: </strong>Between July 2007 and October 2018, 475 patients with colorectal cancer with liver metastases (CRLM) who underwent liver resection were retrospectively reviewed. Sixty-five patients with SCRLM + SEHD were identified and included in the study. Clinical pathological data of these patients were analyzed to evaluate the influence on survival. Important prognostic factors were identified by univariate and multivariate analyses. The risk score system and decision tree analysis were generated according to the important prognostic factors for better patient selection.</p><p><strong>Results: </strong>The 5-year survival rate of patients with SCRLM + SEHD was 21.9%. The most important prognostic factors were SCRLM number of more than five, site of SEHD other than the lung only, inability to achieve SCRLM + SEHD R0 resection, and BRAF mutation of cancer cells. The proposed risk score system and decision tree model easily discriminated between patients with different survival rates and identified the profile of suitable surgical patients.</p><p><strong>Conclusion: </strong>Liver surgery should not be a contraindication for patients with SCRLM + SEHD. Patients with complete SCRLM + SEHD R0 resection, SCRLM number less than or equal to five, SEHD confined to the lung only, and wild-type BRAF could have favorable survival outcomes. The proposed scoring system and decision tree model may be beneficial to patient selection in clinical use.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 8","pages":"732-739"},"PeriodicalIF":3.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9961025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease. 2023台湾脑卒中学会颅内动脉粥样硬化性疾病患者管理指南。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1097/JCMA.0000000000000952
Chun-Jen Lin, Chih-Ping Chung, Nien-Chen Liao, Po-Lin Chen, Nai-Fang Chi, Yen-Jun Lai, Chih-Wei Tang, Chia-Hung Wu, Feng-Chi Chang, Chao-Bao Luo, Li-Yu Fay, Chun-Fu Lin, Chung-Hsing Chou, Tsong-Hai Lee, Jiunn-Tay Lee, Jiann-Shing Jeng, I-Hui Lee

Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, especially in Asian populations, which has a high risk of recurrent stroke and cardiovascular comorbidities. The present guidelines aim to provide updated evidence-based recommendations for diagnosis and management of patients with ICAD. Taiwan Stroke Society guideline consensus group developed recommendations for management of patients with ICAD via consensus meetings based on updated evidences. Each proposed class of recommendation and level of evidence was approved by all members of the group. The guidelines cover six topics, including (1) epidemiology and diagnostic evaluation of ICAD, (2) nonpharmacological management of ICAD, (3) medical therapy for symptomatic ICAD, (4) endovascular thrombectomy and rescue therapy for acute ischemic stroke with underlying ICAD, (5) endovascular interventional therapy for postacute symptomatic intracranial arterial stenosis, and (6) surgical treatment of chronic symptomatic intracranial arterial stenosis. Intensive medical treatment including antiplatelet therapy, risk factor control, and life style modification are essential for patients with ICAD.

颅内动脉粥样硬化性疾病(ICAD)是缺血性卒中的主要原因,特别是在亚洲人群中,它具有复发性卒中和心血管合并症的高风险。本指南旨在为ICAD患者的诊断和管理提供最新的循证建议。台湾脑卒中学会指南共识小组根据最新证据通过共识会议制定了ICAD患者管理建议。每个建议的类别和证据水平都得到了小组所有成员的批准。指南涵盖六个主题,包括(1)ICAD的流行病学和诊断评价,(2)ICAD的非药物治疗,(3)症状性ICAD的药物治疗,(4)伴有ICAD的急性缺血性卒中的血管内血栓切除术和抢救治疗,(5)急性后症状性颅内动脉狭窄的血管内介入治疗,(6)慢性症状性颅内动脉狭窄的手术治疗。包括抗血小板治疗、危险因素控制和生活方式改变在内的强化治疗对ICAD患者至关重要。
{"title":"The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease.","authors":"Chun-Jen Lin,&nbsp;Chih-Ping Chung,&nbsp;Nien-Chen Liao,&nbsp;Po-Lin Chen,&nbsp;Nai-Fang Chi,&nbsp;Yen-Jun Lai,&nbsp;Chih-Wei Tang,&nbsp;Chia-Hung Wu,&nbsp;Feng-Chi Chang,&nbsp;Chao-Bao Luo,&nbsp;Li-Yu Fay,&nbsp;Chun-Fu Lin,&nbsp;Chung-Hsing Chou,&nbsp;Tsong-Hai Lee,&nbsp;Jiunn-Tay Lee,&nbsp;Jiann-Shing Jeng,&nbsp;I-Hui Lee","doi":"10.1097/JCMA.0000000000000952","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000952","url":null,"abstract":"<p><p>Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, especially in Asian populations, which has a high risk of recurrent stroke and cardiovascular comorbidities. The present guidelines aim to provide updated evidence-based recommendations for diagnosis and management of patients with ICAD. Taiwan Stroke Society guideline consensus group developed recommendations for management of patients with ICAD via consensus meetings based on updated evidences. Each proposed class of recommendation and level of evidence was approved by all members of the group. The guidelines cover six topics, including (1) epidemiology and diagnostic evaluation of ICAD, (2) nonpharmacological management of ICAD, (3) medical therapy for symptomatic ICAD, (4) endovascular thrombectomy and rescue therapy for acute ischemic stroke with underlying ICAD, (5) endovascular interventional therapy for postacute symptomatic intracranial arterial stenosis, and (6) surgical treatment of chronic symptomatic intracranial arterial stenosis. Intensive medical treatment including antiplatelet therapy, risk factor control, and life style modification are essential for patients with ICAD.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 8","pages":"697-714"},"PeriodicalIF":3.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9972998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ChatGPT failed Taiwan's Family Medicine Board Exam. ChatGPT未通过台湾家庭医学委员会考试。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1097/JCMA.0000000000000946
Tzu-Ling Weng, Ying-Mei Wang, Samuel Chang, Tzeng-Ji Chen, Shinn-Jang Hwang

Background: Chat Generative Pre-trained Transformer (ChatGPT), OpenAI Limited Partnership, San Francisco, CA, USA is an artificial intelligence language model gaining popularity because of its large database and ability to interpret and respond to various queries. Although it has been tested by researchers in different fields, its performance varies depending on the domain. We aimed to further test its ability in the medical field.

Methods: We used questions from Taiwan's 2022 Family Medicine Board Exam, which combined both Chinese and English and covered various question types, including reverse questions and multiple-choice questions, and mainly focused on general medical knowledge. We pasted each question into ChatGPT and recorded its response, comparing it to the correct answer provided by the exam board. We used SAS 9.4 (Cary, North Carolina, USA) and Excel to calculate the accuracy rates for each question type.

Results: ChatGPT answered 52 questions out of 125 correctly, with an accuracy rate of 41.6%. The questions' length did not affect the accuracy rates. These were 45.5%, 33.3%, 58.3%, 50.0%, and 43.5% for negative-phrase questions, multiple-choice questions, mutually exclusive options, case scenario questions, and Taiwan's local policy-related questions, with no statistical difference observed.

Conclusion: ChatGPT's accuracy rate was not good enough for Taiwan's Family Medicine Board Exam. Possible reasons include the difficulty level of the specialist exam and the relatively weak database of traditional Chinese language resources. However, ChatGPT performed acceptably in negative-phrase questions, mutually exclusive questions, and case scenario questions, and it can be a helpful tool for learning and exam preparation. Future research can explore ways to improve ChatGPT's accuracy rate for specialized exams and other domains.

背景:聊天生成预训练转换器(ChatGPT), OpenAI Limited Partnership, San Francisco, CA, USA,是一种人工智能语言模型,由于其庞大的数据库和解释和响应各种查询的能力而受到欢迎。虽然它已经被不同领域的研究人员测试过,但它的性能因领域而异。我们的目的是进一步测试它在医学领域的能力。方法:采用台湾2022年家庭医学委员会考试试题,采用中英文结合,题型多样,包括反题和选择题,以医学常识为主。我们将每个问题粘贴到ChatGPT中,并记录其回答,将其与考试委员会提供的正确答案进行比较。我们使用SAS 9.4 (Cary, North Carolina, USA)和Excel计算每个问题类型的准确率。结果:ChatGPT答对了125个问题中的52个,正确率为41.6%。问题的长度不影响准确率。否定短语题、多项选择题、互斥选项题、案例情景题和台湾地方政策题的比例分别为45.5%、33.3%、58.3%、50.0%和43.5%,差异无统计学意义。结论:ChatGPT在台湾家庭医学委员会考试中准确率不高。可能的原因包括专科考试的难度和相对薄弱的传统汉语资源数据库。然而,ChatGPT在否定短语问题、互斥问题和案例场景问题中的表现还可以接受,它可以成为学习和考试准备的有用工具。未来的研究可以探索如何提高ChatGPT在专业考试和其他领域的准确率。
{"title":"ChatGPT failed Taiwan's Family Medicine Board Exam.","authors":"Tzu-Ling Weng,&nbsp;Ying-Mei Wang,&nbsp;Samuel Chang,&nbsp;Tzeng-Ji Chen,&nbsp;Shinn-Jang Hwang","doi":"10.1097/JCMA.0000000000000946","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000946","url":null,"abstract":"<p><strong>Background: </strong>Chat Generative Pre-trained Transformer (ChatGPT), OpenAI Limited Partnership, San Francisco, CA, USA is an artificial intelligence language model gaining popularity because of its large database and ability to interpret and respond to various queries. Although it has been tested by researchers in different fields, its performance varies depending on the domain. We aimed to further test its ability in the medical field.</p><p><strong>Methods: </strong>We used questions from Taiwan's 2022 Family Medicine Board Exam, which combined both Chinese and English and covered various question types, including reverse questions and multiple-choice questions, and mainly focused on general medical knowledge. We pasted each question into ChatGPT and recorded its response, comparing it to the correct answer provided by the exam board. We used SAS 9.4 (Cary, North Carolina, USA) and Excel to calculate the accuracy rates for each question type.</p><p><strong>Results: </strong>ChatGPT answered 52 questions out of 125 correctly, with an accuracy rate of 41.6%. The questions' length did not affect the accuracy rates. These were 45.5%, 33.3%, 58.3%, 50.0%, and 43.5% for negative-phrase questions, multiple-choice questions, mutually exclusive options, case scenario questions, and Taiwan's local policy-related questions, with no statistical difference observed.</p><p><strong>Conclusion: </strong>ChatGPT's accuracy rate was not good enough for Taiwan's Family Medicine Board Exam. Possible reasons include the difficulty level of the specialist exam and the relatively weak database of traditional Chinese language resources. However, ChatGPT performed acceptably in negative-phrase questions, mutually exclusive questions, and case scenario questions, and it can be a helpful tool for learning and exam preparation. Future research can explore ways to improve ChatGPT's accuracy rate for specialized exams and other domains.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 8","pages":"762-766"},"PeriodicalIF":3.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9961024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: An experience before National Health Insurance reimbursement in Taiwan. 镭-223治疗转移性去势抵抗性前列腺癌的疗效:台湾健保报销前的经验。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1097/JCMA.0000000000000950
Ping-Hsuan Yu, Tzu-Chun Wei, Yen-Hwa Chang, Hsiao-Jen Chung, Eric Yi-Hsiu Huang, Tzu-Ping Lin, William J Huang

Background: Radium-223 (Ra-223), an α-particle-emitting isotope, inhibits bony metastases and prevents patients from skeletal-related events in metastatic castration-resistant prostate cancer (mCRPC). We retrospectively reviewed the treatment response, predictive factors, and adverse events (AEs) of Ra-223 before the National Health Insurance reimbursement in a Taiwanese tertiary institute.

Methods: Patients treated with Ra-223 before January 2019 were enrolled and categorized into progressive disease (PD) and clinical benefits (CB) groups. Laboratory data before and after the treatment were collected, and spider plots concerning percentage changes of alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) were prepared and calculated statistically. CB/PD, baseline ALP, LDH, and PSA levels were also adopted as stratification factors for overall survival (OS).

Results: Among 19 patients included, 5 (26.3%) and 14 (73.4%) belonged to the PD and CB groups, respectively, with no significant difference observed in the baseline laboratory data. The percentage changes in ALP, LDH, and PSA levels after Ra-223 treatment were statistically significant among the two groups (ALP: CB 54.3 ± 21.4% vs PD 77.6 ± 11.8%, p = 0.044; LDH: CB 88.2 ± 22.8% vs PD 138.3 ± 49.0%, p = 0.046; PSA: CB 97.8 ± 61.7% vs PD 277.0 ± 101.1%, p = 0.002). The trends of LDH between the two groups in spider plot were separated significantly. There were no differences in the AEs between the two groups. CB had a longer median OS than the PD group (20.50 months vs 9.43 months, p = 0.009). Patients with LDH <250 U/L at baseline tended to have longer OS but without significance.

Conclusion: The CB rate of Ra-223 was 73.7%. No predictive factor for treatment response was obtained from pretreatment data. The mean percentage changes in ALP, LDH, and PSA levels compared with baseline significantly differed between the CB and PD groups, especially the LDH levels. The CB and PD groups showed different OS, with LDH levels exhibiting the potential to predict OS.

背景:镭-223 (Ra-223)是一种α-粒子发射同位素,可抑制转移性去势抵抗性前列腺癌(mCRPC)的骨转移并防止患者发生骨骼相关事件。本研究回顾台湾某高等专科学校在国民健康保险报销前,Ra-223的治疗反应、预测因素及不良事件(ae)。方法:纳入2019年1月前接受Ra-223治疗的患者,并将其分为进展性疾病(PD)组和临床获益(CB)组。收集治疗前后实验室数据,制作碱性磷酸酶(ALP)、乳酸脱氢酶(LDH)、前列腺特异性抗原(PSA)变化百分比蜘蛛图,进行统计计算。CB/PD、基线ALP、LDH和PSA水平也被作为总生存期(OS)的分层因素。结果:纳入的19例患者中,PD组5例(26.3%),CB组14例(73.4%),实验室基线数据差异无统计学意义。Ra-223治疗后两组患者ALP、LDH、PSA水平变化百分比差异均有统计学意义(ALP: CB 54.3±21.4% vs PD 77.6±11.8%,p = 0.044;LDH: CB 88.2±22.8% vs PD 138.3±49.0%,p = 0.046;PSA: CB 97.8±61.7% vs PD 277.0±101.1%,p = 0.002)。两组蜘蛛小区LDH变化趋势差异有统计学意义。两组的ae无明显差异。CB组的中位生存期长于PD组(20.50个月vs 9.43个月,p = 0.009)。结论:Ra-223的CB率为73.7%。未从预处理数据中获得治疗反应的预测因子。与基线相比,CB组和PD组ALP、LDH和PSA水平的平均百分比变化显著不同,尤其是LDH水平。CB组和PD组表现出不同的OS, LDH水平具有预测OS的潜力。
{"title":"Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: An experience before National Health Insurance reimbursement in Taiwan.","authors":"Ping-Hsuan Yu,&nbsp;Tzu-Chun Wei,&nbsp;Yen-Hwa Chang,&nbsp;Hsiao-Jen Chung,&nbsp;Eric Yi-Hsiu Huang,&nbsp;Tzu-Ping Lin,&nbsp;William J Huang","doi":"10.1097/JCMA.0000000000000950","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000950","url":null,"abstract":"<p><strong>Background: </strong>Radium-223 (Ra-223), an α-particle-emitting isotope, inhibits bony metastases and prevents patients from skeletal-related events in metastatic castration-resistant prostate cancer (mCRPC). We retrospectively reviewed the treatment response, predictive factors, and adverse events (AEs) of Ra-223 before the National Health Insurance reimbursement in a Taiwanese tertiary institute.</p><p><strong>Methods: </strong>Patients treated with Ra-223 before January 2019 were enrolled and categorized into progressive disease (PD) and clinical benefits (CB) groups. Laboratory data before and after the treatment were collected, and spider plots concerning percentage changes of alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) were prepared and calculated statistically. CB/PD, baseline ALP, LDH, and PSA levels were also adopted as stratification factors for overall survival (OS).</p><p><strong>Results: </strong>Among 19 patients included, 5 (26.3%) and 14 (73.4%) belonged to the PD and CB groups, respectively, with no significant difference observed in the baseline laboratory data. The percentage changes in ALP, LDH, and PSA levels after Ra-223 treatment were statistically significant among the two groups (ALP: CB 54.3 ± 21.4% vs PD 77.6 ± 11.8%, p = 0.044; LDH: CB 88.2 ± 22.8% vs PD 138.3 ± 49.0%, p = 0.046; PSA: CB 97.8 ± 61.7% vs PD 277.0 ± 101.1%, p = 0.002). The trends of LDH between the two groups in spider plot were separated significantly. There were no differences in the AEs between the two groups. CB had a longer median OS than the PD group (20.50 months vs 9.43 months, p = 0.009). Patients with LDH <250 U/L at baseline tended to have longer OS but without significance.</p><p><strong>Conclusion: </strong>The CB rate of Ra-223 was 73.7%. No predictive factor for treatment response was obtained from pretreatment data. The mean percentage changes in ALP, LDH, and PSA levels compared with baseline significantly differed between the CB and PD groups, especially the LDH levels. The CB and PD groups showed different OS, with LDH levels exhibiting the potential to predict OS.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 8","pages":"756-761"},"PeriodicalIF":3.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9961038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron deficiency in Taiwanese patients with heart failure and reduced ejection fraction. 台湾心力衰竭患者缺铁及射血分数降低之研究。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1097/JCMA.0000000000000949
Hsiao-Ping Sung, Chien-Yi Hsu, Ying-Hsiang Lee, Po-Lin Lin, Chia-Te Liao, Fa-Po Chung, Shao-Lun Ko, Chun-Yao Huang, Kuan-Chia Lin, Hung-Yu Chang

Background: Iron deficiency (ID) is a common comorbidity among patients with heart failure and reduced ejection fraction (HFrEF), and is associated with poorer outcomes independent of anemia. This study aimed to evaluate the prevalence and prognostic significance of ID in Taiwanese patients with HFrEF.

Methods: We included HFrEF patients from two multicenter cohorts at different periods. The multivariate Cox regression analysis was applied to assess the risk of outcomes associated with ID, accounting for the varying risk of death.

Results: Of the 3612 patients with HFrEF registered from 2013 to 2018, 665 patients (18.4%) had available baseline iron profile measurements. Of these, 290 patients (43.6%) were iron deficient; 20.2% had ID+/anemia+, 23.4% ID+/anemia-, 21.5% ID-/anemia+, and 34.9% ID-/anemia-. Regardless of anemia status, patients with coexisting ID had a higher risk than those without ID (all-cause mortality: 14.3 vs 9.5 per 100 patient-years, adjusted hazard ratio [HR] 1.33; 95% confidence interval [CI], 0.96-1.85; p = 0.091; cardiovascular mortality: 10.5 per 100 patient-years vs 6.1, adjusted HR 1.54 [95% CI, 1.03-2.30; p = 0.037]; cardiovascular mortality or first unplanned hospitalization for HF: 36.7 vs 19.7 per 100 patient-years, adjusted HR 1.57 [95% CI, 1.22-2.01; p < 0.001]). Among patients eligible for treatment in the IRONMAN trial design (43.9%), parenteral iron therapy was estimated to reduce heart failure hospitalizations and cardiovascular deaths by 13.7 per 100 patient-years.

Conclusion: Iron profiles were tested in less than one-fifth of the Taiwanese HFrEF cohort. ID was present in 43.6% of tested patients and was independently associated with poor prognosis in these patients.

背景:缺铁(ID)是心力衰竭和射血分数降低(HFrEF)患者的常见合并症,与贫血无关的较差预后相关。本研究旨在评估台湾HFrEF患者的ID患病率及预后意义。方法:我们从两个不同时期的多中心队列纳入HFrEF患者。应用多变量Cox回归分析来评估与ID相关的结局风险,考虑到不同的死亡风险。结果:在2013年至2018年登记的3612例HFrEF患者中,665例(18.4%)患者具有可用的基线铁剖面测量值。其中290例(43.6%)缺铁;ID+/贫血+占20.2%,ID+/贫血-占23.4%,ID-/贫血+占21.5%,ID-/贫血-占34.9%。无论贫血状况如何,合并ID患者的风险均高于无ID患者(全因死亡率:14.3 vs 9.5 / 100患者-年,调整后危险比[HR] 1.33;95%置信区间[CI], 0.96-1.85;P = 0.091;心血管死亡率:10.5 / 100患者年vs 6.1,调整后危险度1.54 [95% CI, 1.03-2.30;P = 0.037];心衰的心血管死亡率或首次计划外住院:36.7 vs 19.7 / 100患者年,调整后HR 1.57 [95% CI, 1.22-2.01;P < 0.001])。在IRONMAN试验设计中符合治疗条件的患者中(43.9%),估计肠外铁治疗每100患者年可减少13.7例心力衰竭住院和心血管死亡。结论:在台湾HFrEF队列中,铁谱检测不到五分之一。43.6%的受测患者存在ID,并且与这些患者的不良预后独立相关。
{"title":"Iron deficiency in Taiwanese patients with heart failure and reduced ejection fraction.","authors":"Hsiao-Ping Sung,&nbsp;Chien-Yi Hsu,&nbsp;Ying-Hsiang Lee,&nbsp;Po-Lin Lin,&nbsp;Chia-Te Liao,&nbsp;Fa-Po Chung,&nbsp;Shao-Lun Ko,&nbsp;Chun-Yao Huang,&nbsp;Kuan-Chia Lin,&nbsp;Hung-Yu Chang","doi":"10.1097/JCMA.0000000000000949","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000949","url":null,"abstract":"<p><strong>Background: </strong>Iron deficiency (ID) is a common comorbidity among patients with heart failure and reduced ejection fraction (HFrEF), and is associated with poorer outcomes independent of anemia. This study aimed to evaluate the prevalence and prognostic significance of ID in Taiwanese patients with HFrEF.</p><p><strong>Methods: </strong>We included HFrEF patients from two multicenter cohorts at different periods. The multivariate Cox regression analysis was applied to assess the risk of outcomes associated with ID, accounting for the varying risk of death.</p><p><strong>Results: </strong>Of the 3612 patients with HFrEF registered from 2013 to 2018, 665 patients (18.4%) had available baseline iron profile measurements. Of these, 290 patients (43.6%) were iron deficient; 20.2% had ID+/anemia+, 23.4% ID+/anemia-, 21.5% ID-/anemia+, and 34.9% ID-/anemia-. Regardless of anemia status, patients with coexisting ID had a higher risk than those without ID (all-cause mortality: 14.3 vs 9.5 per 100 patient-years, adjusted hazard ratio [HR] 1.33; 95% confidence interval [CI], 0.96-1.85; p = 0.091; cardiovascular mortality: 10.5 per 100 patient-years vs 6.1, adjusted HR 1.54 [95% CI, 1.03-2.30; p = 0.037]; cardiovascular mortality or first unplanned hospitalization for HF: 36.7 vs 19.7 per 100 patient-years, adjusted HR 1.57 [95% CI, 1.22-2.01; p < 0.001]). Among patients eligible for treatment in the IRONMAN trial design (43.9%), parenteral iron therapy was estimated to reduce heart failure hospitalizations and cardiovascular deaths by 13.7 per 100 patient-years.</p><p><strong>Conclusion: </strong>Iron profiles were tested in less than one-fifth of the Taiwanese HFrEF cohort. ID was present in 43.6% of tested patients and was independently associated with poor prognosis in these patients.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 8","pages":"725-731"},"PeriodicalIF":3.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9961039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on "ChatGPT failed Taiwan's Family Medicine Board Exam". 评论“ChatGPT未通过台湾家庭医学委员会考试”。
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1097/JCMA.0000000000000951
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
{"title":"Comment on \"ChatGPT failed Taiwan's Family Medicine Board Exam\".","authors":"Rujittika Mungmunpuntipantip,&nbsp;Viroj Wiwanitkit","doi":"10.1097/JCMA.0000000000000951","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000951","url":null,"abstract":"","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 8","pages":"775"},"PeriodicalIF":3.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10196155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Long-term outcomes of liver transplantation for alcohol-related liver disease. 酒精相关性肝病肝移植的远期疗效
IF 3 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-08-01 DOI: 10.1097/JCMA.0000000000000940
Niang-Cheng Lin, Chinsu Liu, Cheng-Yen Chen, Hao-Jan Lei, Yi-Fan Tsou, Fang-Cheng Kuo, Shu-Cheng Chou, Meng-Hsuan Chung, Cheng-Yuan Hsia, Che-Chuan Loong, Shen-Chih Wang, Oscar K Lee, Hsin-Lin Tsai

Background: Liver transplantation (LT) is being increasingly performed for alcohol-related liver disease (ALD). It is unclear whether the increasing frequency of LTs in ALD patients has a negative impact on deceased-donor (DDLT) allocation and whether the current policy of 6 months of abstinence before transplantation effectively prevents recidivism after transplantation or improves long-term outcomes.

Methods: A total of 506 adult LT recipients, including 97 ALD patients, were enrolled. The outcomes of ALD patients were compared with those of non-ALD patients. The 97 ALD patients were further divided into group A (6-month abstinence) and group N (nonabstinence) based on the pretransplant alcohol withdrawal period. The incidence of relapsed drinking and the long-term outcomes were compared between the two groups.

Results: The prevalence of LT for ALD significantly increased after 2016 (27.0% vs 14.0%; p < 0.01), but the frequency of DDLT for ALD remained unchanged (22.6% vs 34.1%, p = 0.210). After a median follow-up of 56.9 months, patient survival was comparable between the ALD and non-ALD patients (1, 3, and 5 years posttransplant: 87.6%, 84.3%, and 79.5% vs 82.8%, 76.6%, and 72.2%, respectively; p = 0.396). The results were consistent irrespective of the transplant type and disease severity. In ALD patients, 22 of the 70 (31.4%) patients reported relapsed drinking after transplantation, and the prevalence in group A had a higher tendency than that in group N (38.3% vs 17.4%, p = 0.077). Six months of abstinence or nonabstinence did not result in a survival difference, and de novo malignancies were the leading cause of late patient death in ALD patients.

Conclusion: LT achieves favorable outcomes for ALD patients. Six months of abstinence pretransplant did not predict the risk of recidivism after transplantation. The high incidence of de novo malignancies in these patients warrants a more comprehensive physical evaluation and better lifestyle modifications to improve long-term outcomes.

背景:肝移植(LT)越来越多地被用于治疗酒精相关性肝病(ALD)。目前尚不清楚ALD患者肝移植频率的增加是否会对死亡供体(DDLT)的分配产生负面影响,以及目前移植前6个月禁欲的政策是否能有效预防移植后再犯或改善长期预后。方法:共纳入506名成人肝移植受体,包括97名ALD患者。将ALD患者与非ALD患者的预后进行比较。根据移植前酒精戒断时间将97例ALD患者进一步分为A组(戒酒6个月)和N组(不戒酒)。比较两组饮酒复发的发生率及长期疗效。结果:2016年之后,ALD的LT患病率显著增加(27.0% vs 14.0%;p < 0.01),但ALD的DDLT发生率保持不变(22.6% vs 34.1%, p = 0.210)。中位随访56.9个月后,ALD患者和非ALD患者的生存率相当(移植后1、3和5年:分别为87.6%、84.3%和79.5% vs 82.8%、76.6%和72.2%;P = 0.396)。无论移植类型和疾病严重程度如何,结果都是一致的。70例ALD患者中有22例(31.4%)报告移植后饮酒复发,其中A组的患病率高于N组(38.3% vs 17.4%, p = 0.077)。6个月的戒断或不戒断并没有导致生存差异,新发恶性肿瘤是ALD患者晚期死亡的主要原因。结论:肝移植治疗ALD患者效果良好。移植前6个月的戒断并不能预测移植后再犯的风险。这些患者的新发恶性肿瘤发生率高,需要更全面的身体评估和更好的生活方式改变,以改善长期预后。
{"title":"Long-term outcomes of liver transplantation for alcohol-related liver disease.","authors":"Niang-Cheng Lin,&nbsp;Chinsu Liu,&nbsp;Cheng-Yen Chen,&nbsp;Hao-Jan Lei,&nbsp;Yi-Fan Tsou,&nbsp;Fang-Cheng Kuo,&nbsp;Shu-Cheng Chou,&nbsp;Meng-Hsuan Chung,&nbsp;Cheng-Yuan Hsia,&nbsp;Che-Chuan Loong,&nbsp;Shen-Chih Wang,&nbsp;Oscar K Lee,&nbsp;Hsin-Lin Tsai","doi":"10.1097/JCMA.0000000000000940","DOIUrl":"https://doi.org/10.1097/JCMA.0000000000000940","url":null,"abstract":"<p><strong>Background: </strong>Liver transplantation (LT) is being increasingly performed for alcohol-related liver disease (ALD). It is unclear whether the increasing frequency of LTs in ALD patients has a negative impact on deceased-donor (DDLT) allocation and whether the current policy of 6 months of abstinence before transplantation effectively prevents recidivism after transplantation or improves long-term outcomes.</p><p><strong>Methods: </strong>A total of 506 adult LT recipients, including 97 ALD patients, were enrolled. The outcomes of ALD patients were compared with those of non-ALD patients. The 97 ALD patients were further divided into group A (6-month abstinence) and group N (nonabstinence) based on the pretransplant alcohol withdrawal period. The incidence of relapsed drinking and the long-term outcomes were compared between the two groups.</p><p><strong>Results: </strong>The prevalence of LT for ALD significantly increased after 2016 (27.0% vs 14.0%; p < 0.01), but the frequency of DDLT for ALD remained unchanged (22.6% vs 34.1%, p = 0.210). After a median follow-up of 56.9 months, patient survival was comparable between the ALD and non-ALD patients (1, 3, and 5 years posttransplant: 87.6%, 84.3%, and 79.5% vs 82.8%, 76.6%, and 72.2%, respectively; p = 0.396). The results were consistent irrespective of the transplant type and disease severity. In ALD patients, 22 of the 70 (31.4%) patients reported relapsed drinking after transplantation, and the prevalence in group A had a higher tendency than that in group N (38.3% vs 17.4%, p = 0.077). Six months of abstinence or nonabstinence did not result in a survival difference, and de novo malignancies were the leading cause of late patient death in ALD patients.</p><p><strong>Conclusion: </strong>LT achieves favorable outcomes for ALD patients. Six months of abstinence pretransplant did not predict the risk of recidivism after transplantation. The high incidence of de novo malignancies in these patients warrants a more comprehensive physical evaluation and better lifestyle modifications to improve long-term outcomes.</p>","PeriodicalId":17251,"journal":{"name":"Journal of the Chinese Medical Association","volume":"86 8","pages":"748-755"},"PeriodicalIF":3.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9969621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the Chinese Medical Association
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1